Fatemeh Ostadhossein1, Santosh K Misra1, Prabuddha Mukherjee1, Alireza Ostadhossein2, Enrique Daza1, Saumya Tiwari1, Shachi Mittal1, Mark C Gryka1, Rohit Bhargava3, Dipanjan Pan4,5. 1. Department of Bioengineering, University of Illinois at Urbana-Champaign, 1304 W. Springfield Ave., Urbana, IL, 61801, USA. 2. Department of Engineering Science and Mechanics, Pennsylvania State University, University Park, PA, 16802, USA. 3. Departments of Bioengineering, Electrical and Computer Engineering, Chemical and Biomolecular Engineering, Chemistry, and Mechanical Science and Engineering, Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, 1304 W. Springfield Ave., Urbana, IL, 61801, USA. 4. Carle Foundation Hospital, 502 N. Busey St., Urbana, IL, 61801, USA. 5. Departments of Bioengineering and Materials Science and Engineering, Beckman Institute for Advanced Science and Technology, Institute for Sustainability in Energy and Environment, 502 N. Busey St., Urbana, IL, 61801, USA.
Abstract
Signal transducer and activator of transcription factor 3 (STAT-3) is known to be overexpressed in cancer stem cells. Poor solubility and variable drug absorption are linked to low bioavailability and decreased efficacy. Many of the drugs regulating STAT-3 expression lack aqueous solubility; hence hindering efficient bioavailability. A theranostics nanoplatform based on luminescent carbon particles decorated with cucurbit[6]uril is introduced for enhancing the solubility of niclosamide, a STAT-3 inhibitor. The host-guest chemistry between cucurbit[6]uril and niclosamide makes the delivery of the hydrophobic drug feasible while carbon nanoparticles enhance cellular internalization. Extensive physicochemical characterizations confirm successful synthesis. Subsequently, the host-guest chemistry of niclosamide and cucurbit[6]uril is studied experimentally and computationally. In vitro assessments in human breast cancer cells indicate approximately twofold enhancement in IC50 of drug. Fourier transform infrared and fluorescence imaging demonstrate efficient cellular internalization. Furthermore, the catalytic biodegradation of the nanoplatforms occur upon exposure to human myeloperoxidase in short time. In vivo studies on athymic mice with MCF-7 xenograft indicate the size of tumor in the treatment group is half of the controls after 40 d. Immunohistochemistry corroborates the downregulation of STAT-3 phosphorylation. Overall, the host-guest chemistry on nanocarbon acts as a novel arsenal for STAT-3 inhibition.
Signal transducer and activator of transcription factor 3 (n class="Gene">STAT-3) is known to be overexpressed in cancer stem cells. Poor solubility and variable drug absorption are linked to low bioavailability and decreased efficacy. Many of the drugs regulating STAT-3 expression lack aqueous solubility; hence hindering efficient bioavailability. A theranostics nanoplatform based on luminescent carbon particles decorated with cucurbit[6]uril is introduced for enhancing the solubility of niclosamide, a STAT-3 inhibitor. The host-guest chemistry between cucurbit[6]uril and niclosamide makes the delivery of the hydrophobic drug feasible while carbon nanoparticles enhance cellular internalization. Extensive physicochemical characterizations confirm successful synthesis. Subsequently, the host-guest chemistry of niclosamide and cucurbit[6]uril is studied experimentally and computationally. In vitro assessments in humanbreast cancer cells indicate approximately twofold enhancement in IC50 of drug. Fourier transform infrared and fluorescence imaging demonstrate efficient cellular internalization. Furthermore, the catalytic biodegradation of the nanoplatforms occur upon exposure to humanmyeloperoxidase in short time. In vivo studies on athymic mice with MCF-7 xenograft indicate the size of tumor in the treatment group is half of the controls after 40 d. Immunohistochemistry corroborates the downregulation of STAT-3 phosphorylation. Overall, the host-guest chemistry on nanocarbon acts as a novel arsenal for STAT-3 inhibition.
Authors: Frank Biedermann; Vanya D Uzunova; Oren A Scherman; Werner M Nau; Alfonso De Simone Journal: J Am Chem Soc Date: 2012-09-10 Impact factor: 15.419
Authors: Manas R Gartia; Zhe Wu; Arun K De; Mao Ye; Santosh K Misra; Goutam Ghoshal; Corinne R Bromfield; Emery M Williams; Kuldeep Singh; Krishnarao V Tangella; Laurie Rund; Klaus Schulten; Lawrence B Schook; Partha S Ray; Everette C Burdette; Dipanjan Pan Journal: ACS Nano Date: 2015-10-12 Impact factor: 15.881
Authors: C Parker Gibbs; Valery G Kukekov; John D Reith; Olga Tchigrinova; Oleg N Suslov; Edward W Scott; Steven C Ghivizzani; Tatyana N Ignatova; Dennis A Steindler Journal: Neoplasia Date: 2005-11 Impact factor: 5.715
Authors: Twan Lammers; Peter Peschke; Rainer Kühnlein; Vladimir Subr; Karel Ulbrich; Peter Huber; Wim Hennink; Gert Storm Journal: Neoplasia Date: 2006-10 Impact factor: 5.715
Authors: Rui Li; Zhongliang Hu; Shi-Yong Sun; Zhuo G Chen; Taofeek K Owonikoko; Gabriel L Sica; Suresh S Ramalingam; Walter J Curran; Fadlo R Khuri; Xingming Deng Journal: Mol Cancer Ther Date: 2013-07-26 Impact factor: 6.261